Summary:
- Regulus Therapeutics (RGLS, Financial) has seen a significant 42.34% increase in stock price over the last month.
- Analysts project an average price target of $11.80, suggesting a 240.55% upside potential from the current price.
- The company's drug candidate, Farabursen, shows promising Phase 1b results for treating Orphan Kidney Disease.
Regulus Therapeutics: A Potential Breakthrough in Penny Stocks
Regulus Therapeutics (RGLS) is catching the attention of savvy investors with its impressive stock performance, boasting a noteworthy 42.34% rise in just a month. The excitement largely stems from the promising Phase 1b results of their leading drug candidate, Farabursen, aimed at treating Orphan Kidney Disease. This development hints at an exciting potential upside of 284.62%, positioning Regulus as a penny stock worth watching.
Wall Street Analysts Forecast
According to insights from five top analysts, Regulus Therapeutics Inc (RGLS, Financial) holds an average price target of $11.80 over the next year. The targeted range spans from a high estimate of $28.00 to a low of $6.00, indicating a significant potential upside of 240.55% from its current valuation of $3.47. For a deeper analysis, investors can explore further details on the Regulus Therapeutics Inc (RGLS) Forecast page.
Brokerage Recommendations
The consensus from six brokerage firms currently pegs Regulus Therapeutics Inc's (RGLS, Financial) average recommendation at 1.7, which corresponds to an "Outperform" rating. On a scale where 1 denotes a Strong Buy and 5 indicates a Sell, this suggests a strong optimism among analysts regarding Regulus's future performance.
With its encouraging drug trial results and optimistic analyst projections, Regulus Therapeutics presents a compelling opportunity for investors seeking substantial growth potential in the biotech sector.
